Senology.org - Newsletter

International Senologic and Oncologic  Scientific Community (ISOSC) 

"Connecting specialists worldwide"

 Editor-in-Chief: Gian Paolo Andreoletti, MD

Subscribe       Unsubscribe       Contact       Back Issues     

 

Connecting Specialists Worldwide

Join us on  LinkedIn, ResearchGate, Doctorsbook, Twitter, Facebook, Google Groups, YouTube, SlideShare, Flickr, and share informations and opinions. Check out Senology.org Newspaper and follow our RSS feeds for real-time updates

Literature Selection

Comment

Discussion

  •   - "BRCA1 testing should be offered to women with triple-negative breast cancer diagnosed below 50 years"  - Share your opinion on  LinkedIn®

Calendar of Events

Fragments of History

Literature Selection

Healthcare Companies News

Literature Selection

 

Senology.org collaborates with TalkAboutHealth.com - "Cancer questions, answers, and support". Follow the Expert Q&A Workshops and join the conversation.

TalkAboutHealth Q&A of the month 

"Genetic mutations play a key role in NSCLC. Identifying certain, key mutations can help select targeted therapy. The two most important mutations in lung cancer right now are the EGFR and EML-4ALK mutation and are found in the subtype of lung cancer called adenocarcinoma. These mutations are more commonly found in female, asian, non-smokers. However, they are also found in smokers and males, but to a lesser degree. Patients with the EGFR mutation are generally treated with Tarceva as first line treatment, rather than chemotherapy. Similarly, patients with the EML-4 ALK mutation are treated with a recently approved drug  called Xalqori (Crizotinib). Generally patients with these mutations who are treated with the appropriate drug do very well when compared to patients who don't have the mutation and are treated with chemotherapy. It is important to note, that while other mutations in lung cancer do exist and can be identified (KRAS mutation, PIK-3 mutation, MET to name a few), there are no approved drugs that target these mutations like Tarceva and Xalqori do for EGFR and EML-4ALK and thus patients with these mutations are treated with standard chemotherpay. That said, there are several clinical trials open looking a new drugs that target these mutations" 
(Answer by Benjamin Levy, Assistant Professor of Medicine at Albert Einstein College of Medicine and an attending physician at Continuum Cancer Centers of New York)

 

 

Unsubscribe

     

www.senology.org